Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma-Reference-Cited by-同舟云学术

Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma

Published:2014-12-03 Issue:12 Volume:136 Page:2761-2774
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Bernard Sophie¹²³,Danglade Damien³,Gardano Laura¹²,Laguillier Christelle⁴,Lazarian Gregory³,Roger Claudine³,Thieblemont Catherine⁵,Marzec Jacek⁶,Gribben John⁶,Cymbalista Florence¹²³,Varin-Blank Nadine¹²,Ledoux Dominique¹²,Baran-Marszak Fanny¹²³

Affiliation:

1. U978 Institut National de la Santé et de la Recherche Médicale; Bobigny France

2. Labex Inflamex, Université Paris 13; Sorbonne Paris Cité Bobigny France

3. Service d'Hématologie Biologique, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris; Bobigny France

4. Service de Biochimie, Hôpital Jean Verdier, Assistance Publique-Hôpitaux de Paris; Bondy France

5. Hématologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris; Paris France

6. Barts Cancer Institute, Queen Mary, University of London; London United Kingdom

Funder

Fondation ARC pour la recherche sur le cancer

Institut national du cancer INCA

LABEX INFLAMEX

University Paris 13

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference52 articles.

1. Improvement of overall survival in advanced stage mantle cell lymphoma;Herrmann;J Clin Oncol,2009

2. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies;Advani;J Clin Oncol,2013

3. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma;Wang;N Engl J Med,2013

4. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia;Friedberg;Blood,2010

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies;Acta Haematologica;2024-06-05

2. Identification of the Axis β-Catenin–BTK in the Dynamic Adhesion of Chronic Lymphocytic Leukemia Cells to Their Microenvironment;International Journal of Molecular Sciences;2023-12-18

3. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma;Investigational New Drugs;2023-07-08

4. Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases;Pharmaceuticals;2023-03-07

5. Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib;Scientific Reports;2023-03-07